This browser is no longer supported

Washington, D.C., July 30, 2020 – At today’s White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider donating plasma toward the development of a potential hyperimmune globulin to treat people with serious complications from COVID-19.

The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect.

Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care.

Less than a third of surveyed healthcare professionals (HCPs) in Australia encounter a rare disease patient more than once every six months.

Across APAC, 94% of rare conditions have no approved medical treatment, highlighting need to shift towards the provision of non-medical services.

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia